? miRNA profiling (primary vs recurrent) Between patients cohort (n=6)

Slides:

Advertisements

Similar presentations

Last class Overall goal for labs 7-9 How to pick candidate miRNA targets Overview: “Validate” target prediction.

Advertisements

Michael Birrer Ian McNeish New Developments in Biology and Targets of Epithelial Ovarian Cancer.

MicroRNA implication in urinary bladder cancer A. Zaravinos 1, J. Radojicic 3, G.I. Lambrou 2, D. Volanis 1,4, D. Delakas 4, E.N. Stathopoulos 3, D.A.

Last class Plasmid isolation from bacteria Paper 2: miRNAs in iPSCs.

Supplemental Figure 1 Expression of UHRF1 detected by TaqMan qRT-PCR and many characteristics of patients were compared by Mann-Whiteney’s U-test. A. Expression.

Scott Kopetz, MD, PhD Department of Gastrointestinal Medical Oncology

Expression profile of oncomiRs and tumor-suppressor miRs in urothelial carcinoma of the bladder Apostolos Zaravinos 1, George I. Lambrou 2, Jelena Radojicic.

Chips? SNPs? or PCR? What do we really want and what do we need? Heinz-Josef Lenz, MD Professor of Medicine Co-Director, Colorectal Center Co-Director,

Altogen Biosystems offers the 786-O Transfection Reagent among a host of 100+ cell line specific In Vitro Transfection Kits. 786-O Transfection Reagent.

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.

Last class Overall goal for labs 7-9 How to pick candidate miRNA targets Overview: “Validate” target prediction.

Products > AGS Transfection Reagent (Gastric Adenocarcinoma, CRL1739) Altogen Biosystems offers the AGS Transfection Reagent among a host of 100+ cell.

Products > SK-OV-3 Transfection Reagent (Human Osteosarcoma) Altogen Biosystems offers the SK-OV-3 Transfection Reagent among a host of 100+ cell line.

Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.

014 - Evaluation of Immunosignature Profile in Medulloblastoma

Products > NCI-H1299 Transfection Reagent (Lung Adenocarcinoma)

Last class Overall goal for labs 7-9

MicroRNA-34a: a key regulator in the hallmarks of renal cell carcinoma

OPN -443C>T Genetic Polymorphism and Tumor OPN Expression are Associated with the Risk and Clinical Features of Papillary Thyroid Cancer in a Chinese Cohort.

Products > HT-29 Transfection Reagent (Colorectal Adenocarcinoma)

Products > DLD-1 Transfection Reagent (Colon Cancer, CCL-221)

Supplemental Digital Content 4

Hallett, et al., - Supplementary Figure 1

Anna Sapino, Paul Roepman, Sabine C. Linn, Mireille H. J

Genes with Bimodal Expression Are Robust Diagnostic Targets that Define Distinct Subtypes of Epithelial Ovarian Cancer with Different Overall Survival

Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer C.E. Henry, C. Emmanuel, N.

Table 1: Efficiency for target genes

Circulating Exosomal miR-17-5p and miR-92a-3p Predict Pathologic Stage and Grade of Colorectal Cancer Fangfang Fu, Weiqin Jiang, Linfu Zhou, Zhi Chen

A B C Supplementary figure S7

Products > A375 Transfection Reagent (Melanoma Cells, CRL-1619)

Cellular senescence in usual type uterine leiomyoma

A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer Maruja E. Lira, Yoon-La Choi, Sun Min Lim, Shibing Deng, Donghui.

Characterization of microRNA transcriptome in tumor, adjacent, and normal tissues of lung squamous cell carcinoma Jun Wang, MD, PhD, Zhi Li, MD, PhD,

Identification and Validation of Long Noncoding RNA Biomarkers in Human Non–Small- Cell Lung Carcinomas Hui Yu, MD, Qinghua Xu, PhD, Fang Liu, PhD, Xun.

Profiling of a panel of radioresistant prostate cancer cells identifies deregulation of key miRNAs McDermott Niamh , Meunier Armelle , Wong Simon , Buchete.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Copy-number alterations in an archival breast cancer sample.

Anna Sapino, Paul Roepman, Sabine C. Linn, Mireille H. J

Thyroid Transcription Factor-1 Amplification and Expressions in Lung Adenocarcinoma Tissues and Pleural Effusions Predict Patient Survival and Prognosis

Products > NCI-H441 Transfection Reagent (Lung Adenocarcinoma)

Volume 5, Issue 6, Pages e3 (December 2017)

Volume 148, Issue 1, Pages (January 2018)

Volume 9, Issue 3, Pages (March 2006)

AE1/AE3 Rabbit Normal IgG Supplementary Figure S1 White bar = 5 mm

Volume 8, Issue 5, Pages (September 2014)

An Array-Based Analysis of MicroRNA Expression Comparing Matched Frozen and Formalin-Fixed Paraffin-Embedded Human Tissue Samples Xiao Zhang, Jiamin.

A Novel Approach to Detect Programed Death Ligand 1 (PD-L1) Status and Multiple Tumor Mutations Using a Single Non–Small-Cell Lung Cancer (NSCLC) Bronchoscopy.

mRNA level as % relative to

Tumor Spread through Air Spaces Affects the Recurrence and Overall Survival in Patients with Lung Adenocarcinoma >2 to 3 cm Chenyang Dai, MD, Huikang.

Volume 139, Issue 3, Pages (December 2015)

MicroRNAs in cancer: biomarkers, functions and therapy

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

AZA treatment induces a distinct gene-expression pattern in stromal cells. AZA treatment induces a distinct gene-expression pattern in stromal cells. (A-C)

Volume 6, Issue 3, Pages (March 2016)

MicroRNA Expression in Melanocytic Nevi: The Usefulness of Formalin-Fixed, Paraffin- Embedded Material for miRNA Microarray Profiling Martin Glud, Mikkel.

Supplementary Figure S1

Talk outline Brief history of gene-expression profiling for cancer type classification Current commercially available tests - development and performance.

MicroRNAs in cancer: biomarkers, functions and therapy

Cellular senescence in usual type uterine leiomyoma

MicroRNA-22-3p is down-regulated in the plasma of Han Chinese patients with premature ovarian failure Yujie Dang, M.D., Ph.D., Shidou Zhao, Ph.D., Yingying.

DAC treatment activates expression of immunoregulatory genes.

Fig. 4. Paclitaxel promotes the expression of invasive isoforms of MENA in the primary breast cancer microenvironment. Paclitaxel promotes the expression.

Supplementary Figure S5

SAF-1 expression in clinical breast cancer tissues.

Expression of S100A11 in bulk pancreatic tissues (pancreatic cancer, n = 22; IPMN, n = 18; nonneoplastic pancreas, n = 22). Expression of S100A11 in bulk.

Nested RT-PCR of Mammaglobin and CK19 mRNA in plasma and circulating cells of controls (C) and patients (T) with breast cancer. Nested RT-PCR of Mammaglobin.

Reduced klotho expression in pancreatic cancer.

Defining the eTME genes.

A, heatmap of copy number alterations determined by array CGH for a panel of 79 frozen NSCLC samples. A, heatmap of copy number alterations determined.

DO NOT POST #4054 Gene expression Difference (GED) Revealed Immune Function Gene UP- or Down-regulation as Tumor-associated Inflammatory Cell (TAIC) Infiltration.

Presentation transcript:

? miRNA profiling (primary vs recurrent) Between patients cohort (n=6) RT-PCR selected targets (2 miRNA genes) FFPE set (n=22) Fresh frozen set (n=18) Figure 1 Flow chart of our study design. miRNA profiling was performed using TaqMan PCR in a homogenous set of 3 primary advanced and 3 recurrent serous papillary ovarian adenocarcinomas from different patients. Selected miRNA targets (n=4) were validated in a set of primary and recurrent FFPE serous papillary adenocarcinomas (n=24). Correlations were performed between miRNA expression levels and survival features in an independent set of primary advanced serous ovarian cancer samples. We also attempted to determine whether components of the miRNA processing machinery are responsible for miRNA dysregulation in recurrent ovarian cancer. Mechanism for miRNA deregulation expanded ? IHC TMA (n=71) RNA processing machinery RT-PCR (n=22)